Últimas noticias sobre Kezar Life Sciences (NASDAQ:KZR) Bolsa

Kezar Life Sciences

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Kezar Life Sciences Inc

Rosenblatt analyst Chris Brendler maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and maintains $305 price target.

News

Price Target

Analyst Ratings

COIN

Rosenblatt Maintains Buy on Coinbase Global, Maintains $305 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) with a Buy and maintains $7 price target.

Reiteration

ATOS

HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $7 Price Target

Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) reported quarterly sales of $613.00 thousand which missed the analyst consensus estimate of $686.67 thousand by 10.73 percent. This is a 0.99 percent increase over sales of $607.00 thousand the same period last year.

Earnings

Earnings Misses

Upstream Bio Q3 Sales $613.00K Miss $686.67K Estimate

Earnings Beats

NVGS

Navigator Holdings Q4 2024 Adj. EPS $0.38, Sales $144.031M Beat $135.581M Estimate

WIIM

BURU

Nuburu shares are trading higher after the company said it believes its retained intellectual property,  personnel and relationships will allow it to continue operating in the laser technology field, with a focus on defense, semiconductor and industrial manufacturing applications.

SNCR

Synchronoss Technologies shares are trading higher after the company reported better-than-expected Q4 earnings and sales.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Neutral to Neutral.

AGEN

HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral

Rosenblatt analyst Mike Genovese maintains Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Neutral and lowers the price target from $79 to $73.

CIEN

Rosenblatt Maintains Neutral on Ciena, Lowers Price Target to $73

IRBT

iRobot shares are trading lower after the company disclosed substantial doubt about its ability to continue as a going concern.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) from Neutral to Neutral.

GERN

HC Wainwright & Co. Reiterates Neutral on Geronto Neutral

Heinz Launched Dip For Potato Chips, Same Unmistakable Ketchup, New Way To Enjoy

SFIX

Stitch Fix shares are trading higher following strong Q2 earnings and upbeat Q3 guidance.

GRPN

Groupon shares are trading higher after the company reported better-than-expected Q4 revenue results.

Needham analyst Ryan Koontz maintains Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Buy and lowers the price target from $95 to $90.

Needham Maintains Buy on Ciena, Lowers Price Target to $90

Rosenblatt analyst Blair Abernethy upgrades Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) from Neutral to Buy and announces $77 price target.

Upgrades

RBRK

Rosenblatt Upgrades Rubrik to Buy, Announces $77 Price Target

TSLA

Tesla shares are trading higher after CEO Elon Musk on social media announced plans to double US vehicle production within two years.

Whitestone REIT Announced That It Has Signed A Lease With The Picklr To Open A 20,909-square-foot Location At Terravita Marketplace In Scottsdale, Arizona

STEC

Santech Holdings Regains NASDAQ Compliance, Closes Chapter On Minimum Bid Price Violation

TLRY

Tilray Beverages Announced The Distribution Expansion For Runner's High Brewing, Its Non-alcoholic Craft Beer Brand, Across 4,500 New Distribution Points

INTC: 9% &#x7C; <a href="https://www.benzinga.com//node/44271204">TSMC Proposes Joint Venture With Nvidia, AMD And Broadcom To Operate Intel's Factories: Report</a>
&nbsp;
GRPN: 27% &#x7C; <a href="https://www.benzinga.com//node/44262868">Groupon shares are trading higher after the company reported better-than-expected Q4 revenue results.</a>
&nbsp;
SFIX: 24% &#x7C; <a href="https://www.benzinga.com//node/44262293">Stitch Fix shares are trading higher following strong Q2 earnings and upbeat Q3 guidance.</a>

Movers

Trading Ideas

INTC

Market-Moving News for March 12th

Press Releases

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Comments

Kezar Life Sciences

Noticias

Últimas noticias sobre Kezar Life Sciences (NASDAQ:KZR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL